Founded in 2021, YolTech Therapeutics is advancing next-generation in vivo gene-editing therapies for one-time treatments. The company has developed a fully integrated platform that includes proprietary CRISPR nucleases (YolCas), base editors (YolBE), and a sophisticated lipid nanoparticle delivery system (Yol-LNPs). This technology enables precise, efficient, and tissue-specific gene editing across various therapeutic areas. YolTech’s lead program, YOLT-201 for transthyretin amyloidosis (ATTR), was the first in vivo gene-editing therapy in China to enter a Phase I/IIa clinical trial in 2024. The company now has four clinical-stage programs, addressing conditions such as ATTR, familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and β-thalassemia/sickle cell disease (TDT/SCD). Additionally, YOLT-101, a base-editing therapy for familial hypercholesterolemia (HeFH), was the first in vivo base-editing program to receive IND clearance in both China and the United States.
